Federal Register of Legislation - Australian Government

Primary content

PB 41 of 2021 Determinations/Health as made
This instrument amends the National Health (Continued Dispensing – Emergency Measures) Determination 2020 to make changes to the pharmaceutical benefits eligible to be provided as a Continued Dispensing supply to reflect amendments to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), which commence on the same day.
Administered by: Health
Registered 30 Apr 2021
Tabling HistoryDate
Tabled HR11-May-2021
Tabled Senate11-May-2021
To be repealed 12 Aug 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 41 of 2021

 

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated    28 April          2021

 

 

 

 

           

THEA CONNOLLY                       

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

                                           


 

 

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

 

 

 


1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4).

(2) This instrument may also be cited as PB 41 of 2021.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 May 2021.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1]        Schedule 1, entry for Aciclovir

(a)        insert as first entry:

 

Eye ointment 30 mg per g, 4.5 g

Application to the eye

(b)        omit:

 

Eye ointment 30 mg per g, 4.5 g (Acivision)

Application to the eye

[2]        Schedule 1, after entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg

insert:

Cannabidiol

Oral liquid 100 mg per mL, 100 mL

Oral

[3]        Schedule 1, entry for Mesalazine

substitute:

Mesalazine

Enemas 1 g in 100 mL, 7

Rectal

 

Enemas 2 g in 60 mL, 7

Rectal

 

Enemas 4 g in 60 mL, 7

Rectal

 

Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g

Rectal

 

Sachet containing granules, 500 mg per sachet

Oral

 

Sachet containing granules, 1 g per sachet

Oral

 

Sachet containing granules, 1.5 g per sachet

Oral

 

Sachet containing granules, 3 g per sachet

Oral

 

Sachet containing prolonged release granules, 1 g per sachet

Oral

 

Sachet containing prolonged release granules, 2 g per sachet

Oral

 

Sachet containing prolonged release granules, 4 g per sachet

Oral

 

Suppository 1 g

Rectal

 

Suppository (moulded) 1 g

Rectal

 

Tablet 250 mg (enteric coated)

Oral

 

Tablet 500 mg (enteric coated)

Oral

 

Tablet 500 mg (prolonged release)

Oral

 

Tablet 800 mg (enteric coated)

Oral

 

Tablet 1 g (enteric coated)

Oral

 

Tablet 1 g (prolonged release)

Oral

 

Tablet 1.2 g (prolonged release)

Oral

 

Tablet 1.6 g (enteric coated)

Oral

[4]        Schedule 1, entry for Norethisterone with ethinylestradiol

omit:

 

Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets USP

Oral